New omicron sublineages surge, but Pfizer-BioNTech bivalent booster retains effectiveness Post author: Post published:October 30, 2023 Post category:uncategorized The efficacy of the bivalent Pfizer-BioNTech COVID-19 messenger ribonucleic acid (mRNA) vaccine BNT162b2 BA.4/5. You Might Also Like Early food insecurity linked to higher obesity risk in childhood September 16, 2024 Geneoscopy closes $105 M in series C funding round to power next-generation of gastrointestinal diagnostic tests January 9, 2025 Comorbid atopic diseases affect prognosis of alopecia areata January 9, 2025
Geneoscopy closes $105 M in series C funding round to power next-generation of gastrointestinal diagnostic tests January 9, 2025